Nexavar or Sorafenib stops the growth of metastatic thyroid cancer by nearly 5 months - Jellypharmacy.com

20 July 2013, (http://www.jellypharmacy.com/) : The researchers revealed that Sorafenib (Nexavar) stops metastatic thyroid cancer tumor growth. If the FDA (Food and Drug Administration) approves liver and kidney cancer drug Nexavar it would be the first effective agent for the use in radioactive iodine-refractory differentiated thyroid cancer. It is a kinase inhibitor that mediates tumor cell division and growth of tumor blood vessels.

Thyroid cancer is the fastest-increasing cancer worldwide. In females it is the sixth most common cancer. In 90% of cases thyroid cancer can be effectively treated and cured with surgery and radioactive iodine treatment. However, for the remaining 10% who do not respond to standard therapies, the tumors spread and appear in the lymph node, lungs, bones, and other parts of the body.

Until they began using sorafenib, they had no medical options for these patients who suffered due to progression of their disease. Now, they can give patients hope - a breakthrough medication that can stop the progression of the disease for 5 months. This is the first step in a promising series of clinical trials to identify new drugs that are shifting the horizon for patients with advanced thyroid cancer.

Side effects reported among these patients included fatigue, rash, weight loss, diarrhea, elevated blood pressure, and skin reaction. All adverse events are similar to those reported in patients receiving sorafenib for liver and kidney cancers. It is approved by the FDA for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma.

For more please visit us : Label

Jelly Pharmacy 8721 Santa Monica, Los Angeles, California, USA, 84805 16455069344

Wilson is a Medical Student and a freelancer who is specialized in writing health related articles and disease. He is associated with many Pharmacies for whom he writes articles based on generic drugs like Edegra, Zenegra, Penegra, Eriacta and general health related issues.